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The pharmaceutical industry has experienced
sensational revolution over the last six decades. The
first generation novel drug delivery systems (e.g.,
oral sustained release preparations, inhalations,
transdermal patches, etc.) were developed rapidly
during three decades (1950–1980), achieving
high product translational competence. Spansule®
technology comprehended a sustained release of the
drug over a period of 12 hours for the first time in
1952. After four years of that incidence, pressurized
Metered Dose Inhalers (MDI) initiated the history
of inhalation delivery systems. With the approval
of Scop® in 1979, the transdermal patch was made
available in the market. In the second generation
pharmaceutical formulations, the central issue
was focused on nanomedicines and smart delivery
systems. Although the second generation novel drug
delivery systems (e.g., liposomes, nanoparticles,
microspheres, gene delivery systems, etc.) engrossed
lot of focus during 1980-2010, there are very
limited products available in the market currently.
Doxil® (liposomal formulation) evolved as the first
nanomedicine in 1995. The first nanotechnologybased target drug delivery system (Abraxane®) was
made commercially available in the market in 2005.
The marketable and commercial success of these
nano-drug delivery systems/platforms attracted a
large number of followers. Presently, there are about
6,400 platform technologies available worldwide,
out of which 4,800 are active and 41% of these
technologies are injectable dosage forms. Hence it
can be stated that “The new era is all about Complex
Injectable formulations”.
Debjani Singh
Vice President, Parenteral - US Market, Cadila Healthcare,
Ahmedabad, Gujrat State, India

Complex injectable are the medicines that generally
have at least one feature that makes them difficult
to “genericize” under traditional generic approval
approaches. Complex Injectable market is gaining
traction in injectable therapies owing to the increase
in their use in life threatening as well as chronic
disease therapies.
The complexity may be with respect to the Active
Pharmaceutical Ingredient (API) or the product
manufacturing process or route of administration,
or it could even be the delivery device involved.
Due to the higher degree of complexity involved,
the competition for manufacturing such products is
relatively less as it requires major capital investment
for establishment of desired facility. Every
individual product may have unique manufacturing
process requiring specific set of equipment for batch
manufacturing. Therefore, growth in the complex
injectable market is largely driven by their complex
generic formulations. Market for complex injectable
is primarily driven to meet the unmet need of patients
or to encounter increasing rate of chronic diseases,
minimizing toxic effects of drugs through advance
technology platforms, increase in the demand of
self- administration devices for patient convenience,
better product stability or targeted delivery of drug
products.
Complex Injectable (generics) are exceedingly
challenging and it is quite difficult to prove
similarity through pharmaceutical equivalence
or bioequivalence studies. The Food and Drug
Administration (FDA) is keen to learn about the
differences between the Reference listed drug
product and the generic drug product, rather
than their similarity. So there is a requirement of
immense characterization of these products through
orthogonal techniques. Apart from the popular

How to cite this article: Singh D. Rise of Complex Injectable and Drug Device Combination. MJPS 2020; 6(1): 1-2.

Manipal Journal of Pharmaceutical Sciences | March 2020 | Volume 6 | Issue 1

Published by Impressions@MAHE, 2022

1

1

Manipal Journal of Pharmaceutical Sciences, Vol. 6 [2022], Iss. 1, Art. 1
Singh D, et al: Rise of Complex Injectable and Drug Device Combination

liposome and microsphere formulations, the other
platform technologies that are currently available
commercially are: Lipid based products, PEGylated
products, Polymer drug and protein drug conjugates,
Nanoparticle/Nanocrystals, Micelles, Cyclodextrin
complexes, Emulsions, Suspensions, Super Critical
Fluid technology, Linker based technology, just to
name a few. A simple way to start the development
of Complex Injectable is to first assess regulatory
requirements followed by preparing a clear roadmap and development strategy. An early engagement
with FDA would be beneficial before starting any
investment on the manufacturing facility or initiation
of extensive characterization work or biostudy/
clinical trials etc. Product specific guidance issued by
the regulatory agencies are of much help to remain
in right track of development.
The self- administration devices are also called
“Combination products” which may be a combination
of Drug/Device or Biologics/Device or Drug/
Biologics or Drug/Device/Biologics regulated
and sold as a single unit. They are usually prefilled
syringes or cartridges that are inserted into autoinjectors or pen devices. The devices could be reusable or disposable type and may be designed to
deliver single or variable doses. These combination
products are off-late guided by several stringent
regulatory requirements to ensure safety, dosage
accuracy, patient convenience or any other critical
functional tests designated for its intended use and
performance since they are to be used by the patient
himself or herself majorly. Creating strategies for
device development as well as its clinical requirement
at very early stage of product development like
Human Factor study needs would de-risk the
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huge investment and also fulfill all the regulatory
requirements of maintaining a systematic Design
History File.
The next generation injectable that would make a
steady access in the pharmaceutical industry are
micro devices which range from simple tongue
depressors to micro-chip based implants, smart
injector pen platforms to monitor dosage delivery
as well as timings, wearable devices for infusions,
etc. In the future, the discovery of new molecular
entities may be combined simultaneously with
advanced delivery technologies to make the drug
candidates into more ideal and therapeutically
effective formulations.
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